

## HtrA3 Antibody (N-term)

Catalog\_no: AB1170

Applications: WB

Reactivity: H, Rat

Category: 抗原抗体

Size: 100μL/50μL

Immunogen: HUMAN:112-144

Specificity: This HtrA3 antibody is generated from rabbits immunized with a KLH conjugated

synthetic peptide between 112-144 amino acids from the N-terminal region of human

HtrA3.

Dilution: WB,1:1000;WB,1:1000;IHC-P,1:50~100;IHC-P,1:50~100;

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This Purification:

antibody is purified through a protein G column, eluted with high and low pH buffers

and neutralized immediately, followed by dialysis against PBS.

Serine protease HTRA3, 3421-, High-temperature requirement factor A3, Pregnancy-Other name:

related serine protease, HTRA3, PRSP

Isotype: Rabbit Ig

Background: Insulin-like growth factors (IGFs) stimulate the proliferation and differentiation of a vast

> number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including several proteases that cleave the IGF-Binding Proteins. HtrA1 is a 480 aa protein that contains an N-terminus homologous to MAC25 (IGFBP7) with a conserved Kazal-type serine protease inhibitor motif, as well as a Cterminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. HTRA2 is released from mitochondria and inhibits the function of XIAP by direct binding in a way similar to SMAC. Moreover, when overexpressed

> extramitochondrially, HTRA2 induced atypical cell death, which was neither accompanied by a significant increase in caspase activity nor inhibited by caspase inhibitors, including XIAP. A catalytically inactive mutant of HTRA2, however, did not induce cell death. Suzuki et al. (2001) concluded that HTRA2 is a SMAC-like inhibitor of IAP (inhibitor of apoptosis proteins) activity with a serine protease-dependent cell death-

inducing activity.

reference: Nie, G.Y., et al., Biochem. J. 371 (Pt 1), 39-48 (2003).